Clinical Trial Update: Masitinib for the Treatment of Severe Mast Cell Activation Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for masitinib in severe mast cell activation syndrome is in the early stages with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mast Cell Activation Syndrome

Drugs mentioned

• Masitinib (masitinib)

Snippet

Sponsor: AB Science | Conditions: Mast Cell Activation Syndrome | Phase 2 | Status: UNKNOWN